<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous T cell pseudolymphomas</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous T cell pseudolymphomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous T cell pseudolymphomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rein Willemze, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H373511903"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "cutaneous pseudolymphoma" refers to a heterogeneous group of benign skin disorders that simulate cutaneous lymphomas histologically and sometimes clinically. Cutaneous pseudolymphomas can be separated into two major subtypes, pseudolymphomas mimicking a cutaneous B cell lymphoma and pseudolymphomas mimicking a cutaneous T cell lymphoma  (<a class="graphic graphic_table graphicRef102613" href="/z/d/graphic/102613.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>].</p><p>This topic will focus on distinct clinicopathologic entities commonly included in the spectrum of cutaneous T cell pseudolymphomas. Other mimickers of early-stage mycosis fungoides (MF) or primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, as well as human immunodeficiency virus (HIV)- and other immunodeficiency-related CD8<sup>+</sup> cutaneous pseudolymphomas, will be briefly discussed. Cutaneous T cell lymphomas, lymphomatoid papulosis, and cutaneous B cell pseudolymphomas are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/109157.html" rel="external">"Classification of primary cutaneous lymphomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16193.html" rel="external">"Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/103306.html" rel="external">"Primary cutaneous T cell lymphomas, rare subtypes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">"Lymphomatoid papulosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/102748.html" rel="external">"Cutaneous B cell pseudolymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H771979210"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Histologically, cutaneous T cell pseudolymphomas may show a superficial, band-like pattern simulating early patch/plaque-stage mycosis fungoides (MF) or a nodular or diffuse pattern simulating peripheral T cell lymphoma, not otherwise specified (PTCL, NOS) or tumor-stage MF. Examples of the first category include lymphomatoid contact dermatitis, lymphomatoid drug eruptions, and actinic reticuloid. Examples of the second category include persistent arthropod reactions and nodular scabies.</p><p>However, the cause is unknown in most cases. Such idiopathic cutaneous T cell pseudolymphomas may have a band-like, superficial pattern or a nodular or diffuse pattern.</p><p class="headingAnchor" id="H373512003"><span class="h1">ACTINIC RETICULOID</span><span class="headingEndMark"> — </span>Actinic reticuloid, also called chronic actinic dermatitis, is a severe photosensitivity reaction to ultraviolet B (UVB) light, ultraviolet A (UVA) light, and (in some cases) visible light, with histologic features suggesting mycosis fungoides (MF) [<a href="#rid4">4,5</a>]. Actinic reticuloid is an extremely rare disorder and almost exclusively affects older adult men [<a href="#rid6">6-8</a>].</p><p class="headingAnchor" id="H150332351"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Patients with actinic reticuloid present with a pruritic, persistent, eczematous dermatitis with prominent lichenification and/or infiltrated papules and plaques involving sun-exposed skin areas (eg, face, neck, back of the hands, forearms, upper chest)  (<a class="graphic graphic_picture graphicRef101492 graphicRef101494" href="/z/d/graphic/101492.html" rel="external">picture 1A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Chronic actinic dermatitis'</a>.)</p><p class="headingAnchor" id="H25276800"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Histologic examination of a skin biopsy shows eczematous features including acanthosis, spongiosis, and variably dense dermal infiltrates of lymphocytes, histiocytes, eosinophils, plasma cells, and multinucleated dendritic cells [<a href="#rid6">6,7</a>]. These infiltrates contain atypical T cells with medium-sized to large cerebriform and hyperchromatic nuclei similar to those observed in MF and Sézary syndrome  (<a class="graphic graphic_picture graphicRef103382" href="/z/d/graphic/103382.html" rel="external">picture 2</a>). Exocytosis of atypical lymphocytes in the epidermis can be found.</p><p>In contrast to Sézary syndrome, most cases of actinic reticuloid show a CD8<sup>+</sup> T cell phenotype  (<a class="graphic graphic_picture graphicRef103383" href="/z/d/graphic/103383.html" rel="external">picture 3</a>) [<a href="#rid6">6</a>]. Although there are reports of rare cases of erythrodermic cutaneous T cell lymphoma with severe photosensitivity and a CD8<sup>+</sup> immunophenotype mimicking actinic reticuloid, progression of actinic reticuloid to cutaneous T cell lymphoma is unlikely [<a href="#rid7">7,9</a>].</p><p class="headingAnchor" id="H373512039"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of actinic reticuloid is suspected in an older patient presenting with a persistent eczematous eruption affecting primarily the sun-exposed skin. The definitive diagnosis requires a skin biopsy for routine histology and immunophenotyping and the documentation of increased sensitivity (decreased minimum erythema dose [MED]) to UVB, often to UVB and UVA, and occasionally to visible light by phototesting [<a href="#rid5">5,6,8</a>]. Patch testing and photopatch testing may reveal positive reactions to one or more allergens, in particular fragrances and sesquiterpene lactone mix, in a significant number of patients [<a href="#rid2">2,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Chronic actinic dermatitis'</a>.)</p><p class="headingAnchor" id="H85106212"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Immunophenotyping and T cell receptor (TCR) gene rearrangement analysis are useful adjuncts to histopathologic examination to differentiate erythrodermic actinic reticuloid from Sézary syndrome. The latter is defined by the presence of clonally related CD4<sup>+</sup> malignant T cells in the skin and peripheral blood, with a CD4:CD8 ratio greater than 10 in most cases [<a href="#rid10">10</a>]. In contrast, the skin infiltrates of actinic reticuloid show a predominant CD8<sup>+</sup> T cell phenotype, and the peripheral blood often shows a low or even inverse CD4:CD8 ratio [<a href="#rid6">6</a>]. Clonal T cells are not detected in skin or blood of patients with actinic reticuloid [<a href="#rid7">7,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/16193.html" rel="external">"Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"</a>.)</p><p class="headingAnchor" id="H373512057"><span class="h1">LYMPHOMATOID CONTACT DERMATITIS</span><span class="headingEndMark"> — </span>In rare cases, allergic contact dermatitis may show histologic features simulating early-stage mycosis fungoides (MF). Since the term was first coined in 1976, only 23 cases have been reported [<a href="#rid12">12-14</a>].</p><p>Lymphomatoid contact dermatitis has been associated with various allergens, including metals (nickel sulphate, gold, cobalt), rubber chemicals, dyes, and preservatives. Patients present with pruritic erythematous patches or plaques that preferentially involve the abdomen, upper legs, and buttocks, as in early-stage MF [<a href="#rid13">13</a>]. A generalized eruption is rare.</p><p>Histologic examination of a skin biopsy shows a superficial, band-like infiltrate. The epidermis shows variable acanthosis and spongiosis and usually contains only few atypical T cells. Intraepidermal collections of Langerhans cells (CD1a<sup>+</sup>) and small T cells may be present but should not be misinterpreted as true Pautrier's microabscesses as observed in MF. In rare cases, clonal T cell receptor (TCR) gene rearrangements have been detected, but a polyclonal T cell population is present in most cases [<a href="#rid13">13,14</a>].</p><p>A positive patch test to a relevant allergen and the resolution of the skin lesion with avoidance of the offending allergen confirms the diagnosis of lymphomatoid contact dermatitis.</p><p class="headingAnchor" id="H373512063"><span class="h1">LYMPHOMATOID DRUG REACTION</span><span class="headingEndMark"> — </span>Lymphomatoid drug eruptions are the most common mimickers of cutaneous T cell lymphomas. Based upon the clinical and histologic presentation, different types of lymphomatoid drug eruption can be distinguished:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced pseudolymphoma syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS] mimicking a cutaneous T cell lymphoma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug reaction without systemic symptoms mimicking early-stage mycosis fungoides (MF) [<a href="#rid15">15,16</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD30<sup>+</sup> lymphomatoid drug reaction [<a href="#rid17">17-20</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug reaction with the histologic features of a B cell pseudolymphoma (uncommon) [<a href="#rid21">21,22</a>]</p><p></p><p>Lymphomatoid drug eruptions, including most cases of DRESS, usually resolve after withdrawal of the offending drug. Progression of lymphomatoid drug eruptions to true malignant lymphoma has been reported but is exceptional.</p><p class="headingAnchor" id="H57372718"><span class="h2">Drug-induced pseudolymphoma syndrome (DRESS mimicking cutaneous T cell lymphoma)</span><span class="headingEndMark"> — </span>Several terms, including "drug-induced pseudolymphoma syndrome," "anticonvulsant hypersensitivity syndrome," or "drug-induced hypersensitivity syndrome," have been used to indicate severe drug reactions characterized by the combination of a generalized rash, fever, lymphadenopathy, hematologic abnormalities (eosinophilia; presence of atypical lymphocytes), visceral involvement, and histologic features mimicking a cutaneous malignant lymphoma in some cases.</p><p>The term "drug reaction with eosinophilia and systemic symptoms" (DRESS) is now widely used for these severe drug reactions, whether or not they present with histologic features suspicious for cutaneous lymphoma. DRESS is most commonly caused by anticonvulsants, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, sulfonamides, and antibiotics  (<a class="graphic graphic_table graphicRef86760" href="/z/d/graphic/86760.html" rel="external">table 2</a>) [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p>Some patients with DRESS may have clinical, histologic, and hematologic findings that raise suspicion of MF/Sézary syndrome, such as erythroderma, high numbers of circulating Sézary cells, and highly increased CD4:CD8 ratios. However, clonal T cell receptor (TCR) gene rearrangements are detected only in a small minority of these cases [<a href="#rid24">24-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 50 skin biopsies from 36 patients with DRESS, a lichenoid interphase dermatitis with atypical lymphocytes, sometimes resembling Sézary cells, was found in 14 [<a href="#rid26">26</a>]. In most cases these cells had the phenotype of CD8<sup>+</sup>, granzyme B<sup>+</sup>-activated T cells. T cell clonality was found in only one biopsy from a patient who also had a T cell clone in the blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 117 patients with DRESS, 67 percent had circulating atypical T cells [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced pseudo-Sézary syndrome with Sézary cell counts higher than 1000/mm<sup>3</sup>, CD4:CD8 ratio more than 10, and identical clonal TCR gene rearrangements in skin and peripheral blood has been reported in a patient treated with a combination of <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> and <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H373512101"><span class="h2">Drug eruptions without systemic symptoms simulating cutaneous T cell lymphoma</span><span class="headingEndMark"> — </span>Many different drugs have been reported to cause MF-like or CD30<sup>+</sup> lymphomatoid drug reactions with minimal or no systemic involvement. They include anticonvulsants, antidepressants, antihypertensives, beta blockers, calcium channel blockers, diuretics, antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, and biologics [<a href="#rid2">2,17,28-31</a>].</p><p class="headingAnchor" id="H373512107"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>Patients with lymphomatoid drug eruption without systemic involvement may develop a solitary or multiple erythematous nodules or plaques several months after the initiation of the offending drug  (<a class="graphic graphic_picture graphicRef103512" href="/z/d/graphic/103512.html" rel="external">picture 4</a>) [<a href="#rid16">16,27</a>]. Lesions usually resolve after withdrawal of the offending drug. Progression of lymphomatoid drug eruptions to true malignant lymphoma has been reported but is exceptional [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H373512113"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>Histology of drug reactions without systemic symptoms mimicking cutaneous T cell lymphoma shows dense band-like infiltrates of small lymphocytes, histiocytes, and usually eosinophils, admixed with variable numbers of medium-sized atypical T cells with pleomorphic or cerebriform nuclei and/or variable numbers of CD30<sup>+</sup> blast cells. In most cases these atypical cells have a CD4<sup>+</sup> T cell phenotype [<a href="#rid33">33</a>]. Exocytosis of T cells is variable, and in some cases, pseudo-Pautrier's microabscesses containing small T cells, CD1a<sup>+</sup> Langerhans cells, and (sometimes) eosinophils may be observed.</p><p class="headingAnchor" id="H373512119"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Clonal TCR gene rearrangements have been found in a small number of lymphomatoid drug reactions [<a href="#rid27">27,33</a>]. In most cases, a polyclonal pattern is present.</p><p class="headingAnchor" id="H373512131"><span class="h1">IDIOPATHIC (SOLITARY) T CELL PSEUDOLYMPHOMA</span></p><p class="headingAnchor" id="H53030134"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Idiopathic T cell pseudolymphomas usually present as a solitary nodule or plaque most commonly located on the trunk or head  (<a class="graphic graphic_picture graphicRef103522" href="/z/d/graphic/103522.html" rel="external">picture 5</a>). Occasionally, two or more lesions may be present.</p><p class="headingAnchor" id="H373512144"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Idiopathic T cell pseudolymphomas may show two distinct histologic patterns [<a href="#rid34">34,35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superficial, band-like pattern simulating plaque-stage mycosis fungoides (MF)</strong> – These lesions show a dense, superficial infiltrate characteristically showing sharply demarcated lateral and lower borders, and no or only focal infiltration of the epidermis  (<a class="graphic graphic_picture graphicRef103531 graphicRef103532" href="/z/d/graphic/103531.html" rel="external">picture 6A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular/diffuse pattern simulating tumor-stage MF or a peripheral T cell lymphoma, not otherwise specified (PTCL, NOS)</strong> – These lesions show dense, diffuse or nodular infiltrates within the dermis with a tendency to infiltrate the subcutis  (<a class="graphic graphic_picture graphicRef103537" href="/z/d/graphic/103537.html" rel="external">picture 7</a>). Epidermotropism is generally mild or absent. (See  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.)</p><p></p><p>Both types of lesions show a predominance of small to medium-sized CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>-</sup>, and CD30<sup>-</sup> pleomorphic T cells. A small proportion of medium-sized to large pleomorphic cells may be present [<a href="#rid34">34</a>]. Characteristically, scattered medium-sized to large atypical T cells typically express programmed death-1 (PD-1), Bcl-6, and CXCL13, suggesting a common follicular helper T cell phenotype  (<a class="graphic graphic_picture graphicRef103538" href="/z/d/graphic/103538.html" rel="external">picture 8</a>) [<a href="#rid36">36,37</a>]. Scattered large B cells may be surrounded by PD-1<sup>+</sup> T cells forming rosettes [<a href="#rid37">37</a>]. The proliferative rate is generally low. A considerable admixture of reactive CD8<sup>+</sup> T cells, CD20<sup>+</sup> B cells, plasma cells, and histiocytes, including multinucleated giant cells, can also be observed.</p><p class="headingAnchor" id="H53030140"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Clonal T cell receptor (TCR) gene rearrangements are commonly found in idiopathic T cell pseudolymphomas [<a href="#rid34">34,38</a>]. In one study using the BIOMED-2 protocol [<a href="#rid39">39</a>], clonal TCR gene rearrangements were detected in 6 of 9 cases with a superficial, band-like pattern and 9 of 12 cases with a nodular to diffuse pattern [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H373512150"><span class="h2">Differential diagnosis</span></p><p class="headingAnchor" id="H373512158"><span class="h3">Other types of T cell pseudolymphoma</span><span class="headingEndMark"> — </span>Dense atypical band-like infiltrates can also be found in other types of cutaneous T cell pseudolymphomas, such as lymphomatoid drug reactions without systemic symptoms [<a href="#rid34">34,37</a>]. A history of exposure to a high-risk medication (eg, antiseizure medications) and the resolution of the skin lesions after withdrawal of the offending drug help differentiate lymphomatoid drug reaction from idiopathic T cell pseudolymphoma.</p><p class="headingAnchor" id="H373512164"><span class="h3">Mycosis fungoides</span><span class="headingEndMark"> — </span>Differentiation between idiopathic T cell pseudolymphomas and patch/plaque mycosis fungoides (MF) is generally not difficult but requires a careful clinicopathologic correlation [<a href="#rid1">1</a>]. Idiopathic T cell pseudolymphomas usually present with a solitary lesion mainly on the trunk  (<a class="graphic graphic_picture graphicRef103522" href="/z/d/graphic/103522.html" rel="external">picture 5</a>), whereas early-stage MF usually presents with patches and plaques preferentially on non-sun-exposed skin areas, such as the trunk and buttocks  (<a class="graphic graphic_picture graphicRef60650" href="/z/d/graphic/60650.html" rel="external">picture 9</a>).</p><p>Histologic differences between early-stage MF and idiopathic T cell pseudolymphomas include a nearly complete absence of epidermotropism, presence of scattered PD-1<sup>+</sup> medium-sized to large atypical T cells, and a considerable admixture of reactive CD8<sup>+</sup> T cells, CD20<sup>+</sup> B cells, plasma cells, and histiocytes. The same cellular composition is observed in nodular T cell pseudolymphomas and facilitates the differentiation from tumor-stage MF and PTCL, NOS.</p><p>Moreover, the presence of more than 30 percent large T cells, the demonstration of loss of pan-T cell markers, a high proportion of proliferating cells (MIB-1<sup>+</sup>), and the clinical finding of concurrent patches and plaques strongly suggest a diagnosis of malignant lymphoma.</p><p class="headingAnchor" id="H373512170"><span class="h3">Primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder</span><span class="headingEndMark"> — </span>The clinical, histologic, and immunophenotypical characteristics of nodular idiopathic T cell pseudolymphomas are very similar, if not identical, to tumors previously classified as primary cutaneous CD4<sup>+</sup> small/medium pleomorphic T cell lymphoma (PCSM-TCL) presenting with a solitary lesion. Histologic similarities include the presence of scattered medium-sized to large CD4<sup>+</sup> T cells expressing PD-1, many admixed B cells, CD8<sup>+</sup> T cells, and histiocytes, including multinucleated giant cells [<a href="#rid37">37,40,41</a>]. Clonal T cells are found in both conditions and are no longer considered a useful differential diagnostic criterion [<a href="#rid37">37</a>].</p><p>In the fifth edition of the World Health Organization (WHO) classification for tumors of hematopoietic and lymphoid tissues and in the International Consensus Classification of mature lymphoid neoplasms, these lesions are collectively termed "primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder" [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/109157.html" rel="external">"Classification of primary cutaneous lymphomas"</a>.)</p><p>Rare cases of PCSM-TCL that present with generalized skin lesions or rapidly growing bulky tumors, or show a high proliferative fraction, or a very low percentage of admixed CD8<sup>+</sup> T cells, may have a more aggressive clinical course and are better considered as primary cutaneous PTCL, NOS [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.)</p><p class="headingAnchor" id="H373512176"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Idiopathic T cell pseudolymphomas may resolve spontaneously after skin biopsy [<a href="#rid34">34</a>]. Persistent lesions can be treated with intralesional steroids or surgical excision, or in rare instances with radiotherapy [<a href="#rid34">34,38</a>].</p><p>Recurrence of idiopathic T cell pseudolymphoma is uncommon. Patients have an excellent long-term prognosis and do not require further examinations or staging [<a href="#rid34">34,38</a>].</p><p class="headingAnchor" id="H373512182"><span class="h1">LYMPHOMATOID KERATOSIS</span><span class="headingEndMark"> — </span>Lymphomatoid keratosis is clinically and histologically very similar to the superficial mycosis fungoides (MF)-like type of idiopathic T cell pseudolymphoma [<a href="#rid45">45</a>]. It presents in older adults as a solitary scaly plaque that resembles seborrheic keratosis or actinic keratosis.</p><p>Histologic examination shows a dense band-like infiltrate, often with prominent epidermotropism mimicking MF. As in idiopathic T cell pseudolymphoma, there is a considerable admixture of small to medium-sized pleomorphic T cells with CD20<sup>+</sup> B cells. Clonal T cells have been found in about half of the cases [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H373512188"><span class="h1">HIV- AND OTHER IMMUNODEFICIENCY-RELATED CD8+ CUTANEOUS PSEUDOLYMPHOMA</span><span class="headingEndMark"> — </span>HIV-related CD8<sup>+</sup> cutaneous pseudolymphoma is an inflammatory process resulting from a massive infiltration of the skin by activated, oligoclonal, HIV-specific CD8<sup>+</sup> lymphocytes [<a href="#rid46">46</a>]. It has been reported in severely immunocompromised patients and was more common before the introduction of potent antiretroviral therapy (ART).</p><p>Patients present with pruritic erythematous plaques and nodules located in sun-exposed skin areas that may progress to generalized erythroderma [<a href="#rid46">46,47</a>]. Histologic examination shows a dense infiltrate of cytotoxic CD8<sup>+</sup> T cells in the superficial dermis with variable degrees of epidermotropism and folliculotropism. Cellular atypia is usually mild and T cell clonality is generally not detected.</p><p>Regression of the skin lesion after the initiation of ART has been reported [<a href="#rid48">48</a>]. One patient with persistent lesions despite ART was successfully treated with low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid49">49</a>].</p><p>Similar atypical CD8<sup>+</sup> T cell infiltrates, often associated with considerable numbers of histiocytes and/or granulomas, have been reported in patients with various types of immunodeficiency presenting with generalized papulonodular skin lesions [<a href="#rid50">50-52</a>]. In most cases, clonal T cells can be detected. In patients, particularly children, presenting with skin lesions showing clonal CD8<sup>+</sup> T cell infiltrates, thorough investigations to detect a possible immunodeficiency should be performed.</p><p class="headingAnchor" id="H373512194"><span class="h1">OTHER MIMICKERS OF EARLY-STAGE MYCOSIS FUNGOIDES</span><span class="headingEndMark"> — </span>Several benign, inflammatory dermatoses may show histologic features simulating early-stage mycosis fungoides (MF) in rare instances. These include, among others, lichen sclerosus, lichen aureus/pigmented purpuric dermatosis, and early (inflammatory) stage of vitiligo [<a href="#rid53">53-56</a>].</p><p>Common histopathologic findings include a superficial, band-like lymphoid infiltrate and variable infiltration of the lower layers of the epidermis. The infiltrates are predominantly composed of small, sometimes slightly atypical T cells, and clonal T cell receptor (TCR) gene rearrangements can be detected in some cases. A careful clinicopathologic correlation is essential and sufficient to make a correct diagnosis in most cases.</p><p>In a study of 121 cases of lichen sclerosus et atrophicus, histopathologic features mimicking MF were found in 88 of 94 cases (94 percent) of genital lichen sclerosus et atrophicus but not in any of 27 cases of extragenital lichen sclerosus et atrophicus [<a href="#rid57">57</a>]. Clonal TCR gene rearrangements were found in 16 of 33 tested cases.</p><p>The relationship between pigmented purpuric dermatosis and MF is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13757.html" rel="external">"Pigmented purpuric dermatoses (capillaritis)", section on 'Relationship to mycosis fungoides'</a>.)</p><p class="headingAnchor" id="H373512200"><span class="h1">MIMICKERS OF PRIMARY CUTANEOUS CD30+ LYMPHOPROLIFERATIVE DISORDERS</span><span class="headingEndMark"> — </span>CD30 is typically expressed by the neoplastic T cells of primary cutaneous CD30<sup>+</sup> lymphoproliferative diseases such as lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma. However, a wide variety of inflammatory and infectious skin diseases may contain CD30<sup>+</sup> cells [<a href="#rid28">28</a>]. These include viral infections (eg, orf, milker's nodule, herpes virus infections, HIV infections), reactions to arthropod bites, nodular scabies, drug eruptions, and atopic dermatitis. (See  <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">"Lymphomatoid papulosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H57821762"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The term "cutaneous pseudolymphoma" refers to a heterogeneous group of benign skin disorders that simulate cutaneous B and T cell lymphomas histologically and sometimes clinically  (<a class="graphic graphic_table graphicRef102613" href="/z/d/graphic/102613.html" rel="external">table 1</a>). Histologically, cutaneous T cell pseudolymphomas may show a superficial, band-like pattern simulating early patch/plaque-stage mycosis fungoides (MF) or a nodular or diffuse pattern simulating peripheral T cell lymphoma, not otherwise specified (PTCL, NOS) or tumor-stage MF. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Actinic reticuloid</strong> – Actinic reticuloid is a severe photosensitivity reaction with histologic features suggesting MF or Sézary syndrome. The predominance of CD8<sup>+</sup> T cell phenotype and a normal or even reversed CD4:CD8 ratio in the peripheral blood help distinguish actinic reticuloid from a true lymphoma. (See <a class="local">'Actinic reticuloid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphomatoid allergic contact dermatitis</strong> – Rare cases of allergic contact dermatitis may show clinical and histologic features simulating early-stage MF. A positive patch test to a relevant allergen and the resolution of the skin lesion with avoidance of the offending allergen support the diagnosis of allergic contact dermatitis. (See <a class="local">'Lymphomatoid contact dermatitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphomatoid drug eruptions</strong> – Some patients with drug reaction with eosinophilia and systemic symptoms (DRESS), a severe drug reaction predominantly caused by antiepileptics, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, sulfonamides, and antibiotics, may have clinical, histologic, and hematologic findings mimicking MF/Sézary syndrome. The resolution of symptoms after withdrawal of the offending drug supports the diagnosis. (See <a class="local">'Lymphomatoid drug reaction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic T cell pseudolymphoma</strong> – Idiopathic T cell pseudolymphomas usually present as a solitary nodule or plaque most commonly located on the trunk or head. They may have a band-like, superficial pattern or a nodular or diffuse pattern. The absence of epidermotropism, presence of scattered PD-1<sup>+</sup> atypical T cells, and a considerable admixture of reactive CD8<sup>+</sup> T cells, CD20<sup>+</sup> B cells, plasma cells, and histiocytes in both superficial, band-like and nodular T cell pseudolymphomas facilitates the differentiation of idiopathic T cell pseudolymphomas from MF and PTCL, NOS. (See <a class="local">'Idiopathic (solitary) T cell pseudolymphoma'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rijlaarsdam JU, Willemze R. Cutaneous pseudolymphomas: classification and differential diagnosis. Semin Dermatol 1994; 13:187.</a></li><li><a class="nounderline abstract_t">Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998; 38:877.</a></li><li><a class="nounderline abstract_t">Mitteldorf C, Kempf W. Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification. J Cutan Pathol 2020; 47:76.</a></li><li><a class="nounderline abstract_t">Ive FA, Magnus IA, Warin RP, Jones EW. "Actinic reticuloid"; a chronic dermatosis associated with severe photosensitivity and the histological resemblance to lymphoma. Br J Dermatol 1969; 81:469.</a></li><li><a class="nounderline abstract_t">Paek SY, Lim HW. Chronic actinic dermatitis. Dermatol Clin 2014; 32:355.</a></li><li><a class="nounderline abstract_t">Toonstra J, Henquet CJ, van Weelden H, et al. Actinic reticuloid. A clinical photobiologic, histopathologic, and follow-u study of 16 patients. J Am Acad Dermatol 1989; 21:205.</a></li><li><a class="nounderline abstract_t">Sidiropoulos M, Deonizio J, Martinez-Escala ME, et al. Chronic actinic dermatitis/actinic reticuloid: a clinicopathologic and immunohistochemical analysis of 37 cases. Am J Dermatopathol 2014; 36:875.</a></li><li><a class="nounderline abstract_t">Yap LM, Foley P, Crouch R, Baker C. Chronic actinic dermatitis: a retrospective analysis of 44 cases referred to an Australian photobiology clinic. Australas J Dermatol 2003; 44:256.</a></li><li><a class="nounderline abstract_t">Agar N, Morris S, Russell-Jones R, et al. Case report of four patients with erythrodermic cutaneous T-cell lymphoma and severe photosensitivity mimicking chronic actinic dermatitis. Br J Dermatol 2009; 160:698.</a></li><li><a class="nounderline abstract_t">Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133:1703.</a></li><li><a class="nounderline abstract_t">Bakels V, van Oostveen JW, Preesman AH, et al. Differentiation between actinic reticuloid and cutaneous T cell lymphoma by T cell receptor gamma gene rearrangement analysis and immunophenotyping. J Clin Pathol 1998; 51:154.</a></li><li><a class="nounderline abstract_t">Orbaneja JG, Diez LI, Lozano JL, Salazar LC. Lymphomatoid contact dermatitis: a syndrome produced by epicutaneous hypersensitivity with clinical features and a histopathologic picture similar to that of mycosis fungoides. Contact Dermatitis 1976; 2:139.</a></li><li><a class="nounderline abstract_t">Knackstedt TJ, Zug KA. T cell lymphomatoid contact dermatitis: a challenging case and review of the literature. Contact Dermatitis 2015; 72:65.</a></li><li><a class="nounderline abstract_t">Coleman E, Bhawan J. Baby Wet Wipes: An Unusual Culprit of Lymphomatoid Contact Dermatitis Mimicking Mycosis Fungoides. Am J Dermatopathol 2022; 44:205.</a></li><li><a class="nounderline abstract_t">Kardaun SH, Scheffer E, Vermeer BJ. Drug-induced pseudolymphomatous skin reactions. Br J Dermatol 1988; 118:545.</a></li><li><a class="nounderline abstract_t">Rijlaarsdam U, Scheffer E, Meijer CJ, et al. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24:216.</a></li><li><a class="nounderline abstract_t">Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. J Am Acad Dermatol 1998; 38:806.</a></li><li><a class="nounderline abstract_t">Kabashima R, Orimo H, Hino R, et al. CD30-positive T-cell pseudolymphoma induced by amlodipine. J Eur Acad Dermatol Venereol 2008; 22:1522.</a></li><li><a class="nounderline abstract_t">Sawada Y, Yoshiki R, Kawakami C, et al. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol 2010; 90:521.</a></li><li><a class="nounderline abstract_t">Grossmann P, Vanecek T, Steiner P, et al. Novel and recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with Brooke-Spiegler syndrome including the phenotypic variant of multiple familial trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy specimens. Am J Dermatopathol 2013; 35:34.</a></li><li><a class="nounderline abstract_t">Luelmo Aguilar J, Mieras Barceló C, Martín-Urda MT, et al. Generalized cutaneous B-cell pseudolymphoma induced by neuroleptics. Arch Dermatol 1992; 128:121.</a></li><li><a class="nounderline abstract_t">Magro CM, Daniels BH, Crowson AN. Drug induced pseudolymphoma. Semin Diagn Pathol 2018; 35:247.</a></li><li><a class="nounderline abstract_t">Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169:1071.</a></li><li><a class="nounderline abstract_t">D'Incan M, Souteyrand P, Bignon YJ, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome. Arch Dermatol 1992; 128:1371.</a></li><li><a class="nounderline abstract_t">Reeder MJ, Wood GS. Drug-induced pseudo-Sezary syndrome: a case report and literature review. Am J Dermatopathol 2015; 37:83.</a></li><li><a class="nounderline abstract_t">Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol 2015; 173:50.</a></li><li><a class="nounderline abstract_t">Callot V, Roujeau JC, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996; 132:1315.</a></li><li><a class="nounderline abstract_t">Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol 2008; 35:1100.</a></li><li><a class="nounderline abstract_t">Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.</a></li><li><a class="nounderline abstract_t">Saeed SA, Bazza M, Zaman M, Ryatt KS. Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J 2000; 76:577.</a></li><li><a class="nounderline abstract_t">Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol 2009; 19:292.</a></li><li><a class="nounderline abstract_t">Sangueza OP, Cohen DE, Calciano A, et al. Mycosis fungoides induced by phenytoin. Eur J Dermatol 1993; 3:474.</a></li><li><a class="nounderline abstract_t">Magro CM, Crowson AN, Kovatich AJ, Burns F. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol 2003; 34:119.</a></li><li><a class="nounderline abstract_t">Rijlaarsdam JU, Scheffer E, Meijer CJ, Willemze R. Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients. Cancer 1992; 69:717.</a></li><li><a class="nounderline abstract_t">Smolle J, Torne R, Soyer HP, Kerl H. Immunohistochemical classification of cutaneous pseudolymphomas: delineation of distinct patterns. J Cutan Pathol 1990; 17:149.</a></li><li><a class="nounderline abstract_t">Rodríguez Pinilla SM, Roncador G, Rodríguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009; 33:81.</a></li><li><a class="nounderline abstract_t">Cetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36:109.</a></li><li><a class="nounderline abstract_t">Leinweber B, Beltraminelli H, Kerl H, Cerroni L. Solitary small- to medium-sized pleomorphic T-cell nodules of undetermined significance: clinical, histopathological, immunohistochemical and molecular analysis of 26 cases. Dermatology 2009; 219:42.</a></li><li><a class="nounderline abstract_t">Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26:2159.</a></li><li><a class="nounderline abstract_t">Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol 2009; 31:317.</a></li><li><a class="nounderline abstract_t">Alberti-Violetti S, Torres-Cabala CA, Talpur R, et al. Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. J Cutan Pathol 2016; 43:1121.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Garcia-Herrera A, Colomo L, Camós M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008; 26:3364.</a></li><li><a class="nounderline abstract_t">Arai E, Shimizu M, Tsuchida T, et al. Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases. Arch Dermatol 2007; 143:53.</a></li><li><a class="nounderline abstract_t">Bachelez H, Hadida F, Gorochov G. Massive infiltration of the skin by HIV-specific cytotoxic CD8+ T cells. N Engl J Med 1996; 335:61.</a></li><li><a class="nounderline abstract_t">Guitart J, Variakojis D, Kuzel T, Rosen S. Cutaneous CD8 T cell infiltrates in advanced HIV infection. J Am Acad Dermatol 1999; 41:722.</a></li><li><a class="nounderline abstract_t">Schartz NE, De La Blanchardiére A, Alaoui S, et al. Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy. J Am Acad Dermatol 2003; 49:139.</a></li><li><a class="nounderline abstract_t">Ingen-Housz-Oro S, Sbidian E, Ortonne N, et al. HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate. Dermatology 2013; 226:15.</a></li><li><a class="nounderline abstract_t">Marzano AV, Berti E, Alessi E, Caputo R. Clonal CD8 infiltration of the skin in common variable immunodeficiency: a prelymphomatous stage? J Am Acad Dermatol 2001; 44:710.</a></li><li><a class="nounderline abstract_t">Schuetz C, Huck K, Gudowius S, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med 2008; 358:2030.</a></li><li><a class="nounderline abstract_t">Gammon B, Robson A, Deonizio J, et al. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency. J Am Acad Dermatol 2014; 71:555.</a></li><li><a class="nounderline abstract_t">Citarella L, Massone C, Kerl H, Cerroni L. Lichen sclerosus with histopathologic features simulating early mycosis fungoides. Am J Dermatopathol 2003; 25:463.</a></li><li><a class="nounderline abstract_t">Fink-Puches R, Wolf P, Kerl H, Cerroni L. Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides. Arch Dermatol 2008; 144:1169.</a></li><li><a class="nounderline abstract_t">Horn TD, Abanmi A. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Dermatopathol 1997; 19:400.</a></li><li><a class="nounderline abstract_t">Petit T, Cribier B, Bagot M, Wechsler J. Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides. Eur J Dermatol 2003; 13:410.</a></li><li><a class="nounderline abstract_t">Leoni E, Kempf W, Cerroni L. Lichen Sclerosus et Atrophicus With Histopathologic Features Mimicking Mycosis Fungoides: A Large Series of Cases Comparing Genital With Extragenital Lichen Sclerosus. Am J Surg Pathol 2022; 46:83.</a></li></ol></div><div id="topicVersionRevision">Topic 15723 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986687" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cutaneous pseudolymphomas: classification and differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631994" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cutaneous pseudolymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31237707" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4240213" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : "Actinic reticuloid"; a chronic dermatosis associated with severe photosensitivity and the histological resemblance to lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891057" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic actinic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2768570" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Actinic reticuloid. A clinical photobiologic, histopathologic, and follow-u study of 16 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25238449" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic actinic dermatitis/actinic reticuloid: a clinicopathologic and immunohistochemical analysis of 37 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616491" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic actinic dermatitis: a retrospective analysis of 44 cases referred to an Australian photobiology clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067712" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Case report of four patients with erythrodermic cutaneous T-cell lymphoma and severe photosensitivity mimicking chronic actinic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635287" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602691" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Differentiation between actinic reticuloid and cutaneous T cell lymphoma by T cell receptor gamma gene rearrangement analysis and immunophenotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1021341" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lymphomatoid contact dermatitis: a syndrome produced by epicutaneous hypersensitivity with clinical features and a histopathologic picture similar to that of mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25345884" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : T cell lymphomatoid contact dermatitis: a challenging case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34991101" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Baby Wet Wipes: An Unusual Culprit of Lymphomatoid Contact Dermatitis Mimicking Mycosis Fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2967716" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Drug-induced pseudolymphomatous skin reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1826111" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591791" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carbamazepine-induced pseudolymphoma with CD-30 positive cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452522" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CD30-positive T-cell pseudolymphoma induced by amlodipine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20814632" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23249834" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Novel and recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with Brooke-Spiegler syndrome including the phenotypic variant of multiple familial trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346739" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Generalized cutaneous B-cell pseudolymphoma induced by neuroleptics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29361381" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Drug induced pseudolymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855313" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1417026" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25033012" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Drug-induced pseudo-Sezary syndrome: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25630796" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915309" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616762" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844471" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lymphomatoid drug reaction to ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10964126" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cefuroxime induced lymphomatoid hypersensitivity reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336342" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drug-induced CD30+ T cell pseudolymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mycosis fungoides induced by phenytoin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612879" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730122" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2197304" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Immunohistochemical classification of cutaneous pseudolymphomas: delineation of distinct patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987541" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989349" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349695" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Solitary small- to medium-sized pleomorphic T-cell nodules of undetermined significance: clinical, histopathological, immunohistochemical and molecular analysis of 26 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918122" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461234" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27550169" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541895" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224542" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637555" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Massive infiltration of the skin by HIV-specific cytotoxic CD8+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534634" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cutaneous CD8 T cell infiltrates in advanced HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833028" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23343593" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260556" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clonal CD8 infiltration of the skin in common variable immunodeficiency: a prelymphomatous stage?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463379" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An immunodeficiency disease with RAG mutations and granulomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813299" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14631186" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lichen sclerosus with histopathologic features simulating early mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794462" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261477" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Analysis of the lymphocytic infiltrate in a case of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12948929" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34049317" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lichen Sclerosus et Atrophicus With Histopathologic Features Mimicking Mycosis Fungoides: A Large Series of Cases Comparing Genital With Extragenital Lichen Sclerosus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
